`
`ACRUX
`
`Acrux / About Acrux
`
`Board of
`Directors
`
`About Acrux
`
`Management
`Team
`
`Company
`Philosophy
`
`Partnering
`with us
`
`Contact Us
`
`Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and
`
`commercialising specialty and generic topical pharmaceuticals.
`
`Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully
`
`developed and commercialised through licensees a number of pharmaceutical products in
`
`the US and Europe using the Patchless PatchTM, a fast-drying and invisible topical
`
`application technology. Marketed products include Axiron®, Evamist~ and Lenzetto®. More
`
`recently, in addition to specialty products, Acrux has identified and initiated development of a
`
`range of generic products. Acrux is leveraging its on-site laboratories, GMP manufacturing
`
`suite, clinical and commercial experience to bring more products to market. Acrux
`
`encourages collaboration and is well positioned to discuss partnering and product
`
`development.
`
`Products and technology
`
`Currently, we have three pharmaceutical products approved and marketed and are investing
`
`in research to develop further products to meet patients’ needs. Learn more about our
`
`commercialised products.
`
`Acrux’s proprietary technology is covered by broad, well-differentiated, issued
`patents. We continue to develop this technology, expanding the breadth of
`molecules which can be administered topically.
`
`Facilities and capabilities
`
`With onsite laboratories and a GMP manufacturing facility, we can oversee our products from
`
`early development through to clinical trials. We hold a TGA licence for the manufacture of
`
`transdermal and transmucosal products for clinical trials.
`
`Our development processes include, but are not limited to:
`
`http://www.acrux.com.au/about/[lO/27/2016 10:28:44 AM]
`
`ARGENTUM EX1045
`
`Page 1
`
`
`
`Abo~Acmx-Acmx
`
`¯ Analytical method development and validation
`
`¯ Container closure selection
`
`¯ Applicator or device development
`
`¯ Extractables and leachables testing
`
`¯ Stability testing
`
`¯ Manufacturing scale-up and technical transfer to commercial-scale facilities
`
`¯ Performing CMC activities, studies and reports for regulatory submissions
`
`Shareholders
`
`Acrux Limited is a listed entity on the ASX and is a Pooled Development Fund,
`registered under the Pooled Development Fund Act 1992.
`
`Under the Pooled Development Fund Act 1992, shareholders are entitled to
`concessionary tax treatment in Australia for income and capital gains derived in
`connection with their shareholding. Gains realised on the disposal of shares will
`
`not be included in an investors assessable income in Australia. An investor will
`not be entitled to any deduction or capital loss on the sale of shares. Unfranked
`dividends received by an Australian resident will be exempt from tax. Franked
`dividends will also be exempt from tax unless the shareholder elects to be taxed.
`
`An Australian corporate tax entity may credit its franking account (with franking
`credits attaching to a franked dividend), regardless of whether it has elected to
`treat the dividend as exempt or assessable income. Dividends paid to non-
`residents will not be subject to withholding tax. A shareholder or prospective
`shareholder should obtain their own tax advice rather than relying on this
`summary.
`
`ACRUX TIMELINE
`
`ii
`
`http://www.acrux.com.au/about/[10/27/2016 10:28:44 AM]
`
`Page 2
`
`
`
`Abo~Acmx-Acmx
`
`First US patent granted
`
`Acrux listed on ASX
`
`(ACR:ASX)
`
`!
`
`Evamist® launched by KV
`
`Pharmaceutical
`
`Acrux initiates Axiron® Phase
`III clinical trial
`
`Axiron® launched by Eli Lilly
`
`J
`
`Veterinary licensed to Elanco
`
`globally (including
`Recuvyra®)
`
`Evamist® licensed to KV
`
`Pharmaceutical in US
`
`Acrux submits Axiron® NDA
`
`to FDA
`
`Axiron® licensed to Eli Lilly
`
`|
`
`Recuvyra® launched by
`
`Elanco
`
`http://www.acrux.com.au/about/[10/27/2016 10:28:44 AM]
`
`Page 3
`
`
`
`Abo~Acmx-Acmx
`
`Evamist® licensed to Perrigo
`
`in US
`
`Estradiol licensed to Gedeon
`
`Richter; including for EU
`
`III
`
`". _ -:--
`
`Lenzetto® launched in Europe
`
`http://www.acrux.com.au/about/[10/27/2016 10:28:44 AM]
`
`Page 4
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
